Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Chihche Lin"'
Autor:
Qiyu Chen, Ranran Li, ChihChe Lin, Chiming Lai, Dechang Chen, Hongping Qu, Yaling Huang, Wenlian Lu, Yaoqing Tang, Lei Li
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background We aimed to develop an early warning system for real-time sepsis prediction in the ICU by machine learning methods, with tools for interpretative analysis of the predictions. In particular, we focus on the deployment of the system
Externí odkaz:
https://doaj.org/article/9704e5ba19c247c7b3bb8280980cc2f7
Publikováno v:
Applied Clinical Informatics. 14:65-75
Background The lack of information interoperability between different devices and systems in the intensive care unit (ICU) hinders further utilization of data, especially for early warning of specific diseases in the ICU. Objectives We aimed to estab
Autor:
Johann de Bono, Paul Workman, Aram Oganesian, Harold Keer, Chihche Lin, Ruth Riisnaes, Penelope Flohr, Mateus Crespo, Roberta Ferraldeschi, Joel Picus, Jorge Garcia, Fred Saad, Syed Hussain, Susan Slovin
Supplementary Data from Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9277d355e04d8d0cecd899a9da95eec8
https://doi.org/10.1158/1078-0432.22470513.v1
https://doi.org/10.1158/1078-0432.22470513.v1
Autor:
Johann de Bono, Paul Workman, Aram Oganesian, Harold Keer, Chihche Lin, Ruth Riisnaes, Penelope Flohr, Mateus Crespo, Roberta Ferraldeschi, Joel Picus, Jorge Garcia, Fred Saad, Syed Hussain, Susan Slovin
Purpose:Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This phase I/II trial evaluated onalespib in combination with abiraterone acetate (AA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc0717438788a30e083724b9d2bf80f
https://doi.org/10.1158/1078-0432.c.6527595.v1
https://doi.org/10.1158/1078-0432.c.6527595.v1
Publikováno v:
Applied clinical informatics.
The lack of information interoperability between different devices and systems in the intensive care unit (ICU) hinders further utilization of data, especially for early warning of specific diseases in the ICU.We aimed to establish a data integration
BackgroundThe lack of information interoperability between different devices and systems in the ICU hinders further utilization of data, especially for early warning of specific diseases in the ICU.ObjectivesWe aimed to establish a real-time early wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4116fbc0de940fa05020c78750e81f2
https://doi.org/10.1101/2022.07.06.22277188
https://doi.org/10.1101/2022.07.06.22277188
Autor:
Qiyu Chen, Ranran Li, ChihChe Lin, Chiming Lai, Dechang Chen, Hongping Qu, Yaling Huang, Wenlian Lu, Yaoqing Tang, Lei Li
ObjectiveWe aimed to develop an early warning system for real-time sepsis prediction in the ICU by equipping with interpretation analysis and transfer learning tools to improve the feasibility to deploy the sepsis prediction system, particularly to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df33b4f79315fcb33eef65e1561a27ed
https://doi.org/10.1101/2021.05.13.21256281
https://doi.org/10.1101/2021.05.13.21256281
Autor:
Fred Saad, Aram Oganesian, Harold N. Keer, Susan F. Slovin, Ruth Riisnaes, Penelope Flohr, Johann S. de Bono, Mateus Crespo, Roberta Ferraldeschi, Chihche Lin, Joel Picus, Syed A. Hussain, Paul Workman, Jorge A. Garcia
Publikováno v:
Clin Cancer Res
Purpose: Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This phase I/II trial evaluated onalespib in combination with abiraterone acetate (AA)
Autor:
Patricia LoRusso, Simone Jueliger, Harold N. Keer, Chihche Lin, Purvee Kumar, Alain C. Mita, Xiaoping Zhang, Monica M. Mita, Roberta Ferraldeschi, Edwin P. Rock, Anthony W. Tolcher, Michael S. Gordon, Aram Oganesian
Publikováno v:
Molecular Cancer Therapeutics. 17:A091-A091
Background: We report dose escalation results from a phase 1/2 trial of ASTX660 (NCT02503423). This non-peptidomimetic, dual XIAP and cIAP antagonist inhibits tumor cell lines at nanomolar concentrations and is active against xenografts. Methods: Stu
Autor:
Peter J. O'Dwyer, Chihche Lin, Lewis C. Strauss, T.R. Jeffry Evans, Joseph D. Purvis, Eric Van Cutsem, Alexander S. Rosemurgy, Malcolm J. Moore, Francis P. Arena, Elizabeth Armstrong, Michelle Gara, Edwin P. Rock, Jennifer Lee
Publikováno v:
Journal of Clinical Oncology. 30:TPS4134-TPS4134
TPS4134 Background: Dasatinib, a potent oral BCR-ABL and SRC family kinase (SFK) inhibitor, is approved for first- and second-line therapy of Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML) in pts with newly diagnosed CM